Harrow, Inc. (NASDAQ:HROW) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC lowered its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 277,670 shares of the company's stock after selling 16,100 shares during the quarter. Renaissance Technologies LLC owned 0.78% of Harrow worth $9,316,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in HROW. Woodmont Investment Counsel LLC boosted its stake in Harrow by 0.5% during the fourth quarter. Woodmont Investment Counsel LLC now owns 81,400 shares of the company's stock worth $2,731,000 after buying an additional 445 shares during the last quarter. Swiss National Bank raised its holdings in shares of Harrow by 1.0% during the 4th quarter. Swiss National Bank now owns 59,300 shares of the company's stock worth $1,990,000 after acquiring an additional 600 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Harrow by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock valued at $253,000 after purchasing an additional 727 shares during the period. HighTower Advisors LLC increased its position in Harrow by 13.8% during the fourth quarter. HighTower Advisors LLC now owns 10,127 shares of the company's stock worth $340,000 after purchasing an additional 1,227 shares during the last quarter. Finally, Avantax Advisory Services Inc. raised its stake in Harrow by 11.3% during the fourth quarter. Avantax Advisory Services Inc. now owns 12,534 shares of the company's stock worth $421,000 after purchasing an additional 1,273 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on HROW shares. HC Wainwright restated a "buy" rating and set a $57.00 price target on shares of Harrow in a report on Monday, March 31st. B. Riley cut their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st.

Harrow Trading Up 4.3 %

Harrow stock traded up $0.99 during midday trading on Wednesday, reaching $23.90. 100,870 shares of the stock traded hands, compared to its average volume of 503,970. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The firm has a market cap of $852.13 million, a PE ratio of -25.43 and a beta of 0.46. The company has a 50-day simple moving average of $25.81 and a two-hundred day simple moving average of $35.26. Harrow, Inc. has a 12-month low of $9.86 and a 12-month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.14. The business had revenue of $66.83 million for the quarter, compared to analyst estimates of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Research analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.